US Stock MarketDetailed Quotes

REGN Regeneron Pharmaceuticals

Watchlist

582.325
-16.435-2.74%

Trading May 1 09:32 ET

62.87BMarket Cap14.80P/E (TTM)

Regeneron Pharmaceuticals Stock Forum

Movers and Shakers

Apr 29 20:33

Columns Today's Pre-Market Movers and Top Ratings | SPOT, NVO, SOFI, and More

Morning Movers
Gapping Up
$Hims & Hers Health (HIMS.US)$ Hims & Hers surged 34.1% and $Novo-Nordisk A/S (NVO.US)$ increased by 4%. This followed Novo Nordisk's announcement that it will broaden the availability of its weight loss drug Wegovy by offering it through telehealth providers Hims & Hers Health, Ro, and Life MD, now that the drug is no longer facing shortages in the U.S.
$SoFi Technologies (SOFI.US)$ stock rose 5.9% after...

SoFi hits record revenue: Has the turnaround arrived?

Teddy123

Apr 21 12:27

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

$Regeneron Pharmaceuticals (REGN.US)$
Breakthrough: FDA Clears Dupixent for 300,000 Chronic Urticaria Patients After Decade-Long Wait

韭菜变主力

Mar 19 11:50

$Regeneron Pharmaceuticals (REGN.US)$ Sold my trading position at 734. Put a limit buy order at around 600 to wait for the gap fill. The 200 week moving average is a key resistance. The company has to prove the Eylea franchise revenue will not be significantly eroded by biosimilars.

Teddy123

Mar 10 12:26

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

$Regeneron Pharmaceuticals (REGN.US)$
Can Dupixent Transform Rare Skin Disease Treatment? New Trial Data Reveals Breakthrough

韭菜变主力

Mar 7 17:33

$Regeneron Pharmaceuticals (REGN.US)$ higher low?

Teddy123

Feb 28 20:08

Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma

$Regeneron Pharmaceuticals (REGN.US)$
Regeneron's Multiple Myeloma Drug Clears Critical EU Regulatory Hurdle - What's Next?

$Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma$

Teddy123

Feb 26 20:12

Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma

$Regeneron Pharmaceuticals (REGN.US)$
Can Regeneron's Cancer Drug With 80% Response Rate Secure FDA Approval For Lymphoma?

$Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma$

Teddy123

Feb 25 14:11

Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial

$Regeneron Pharmaceuticals (REGN.US)$
Revolutionary Hearing Breakthrough: Can This Gene Therapy End Childhood Genetic Deafness?

TRIUMPHANT RETURNS

Feb 19 06:38

LOTS OF NOTABLE NAMES IN THIS STOCK!

$Novo-Nordisk A/S (NVO.US)$ $Moderna (MRNA.US)$ $Johnson & Johnson (JNJ.US)$ $Netflix (NFLX.US)$ $Uber Technologies (UBER.US)$ $Grab Holdings (GRAB.US)$ $ParkwayLife Reit (C2PU.SG)$ $Tempus AI (TEM.US)$ $Serve Robotics (SERV.US)$ $Tesla (TSLA.US)$ $Regeneron Pharmaceuticals (REGN.US)$ $Amgen (AMGN.US)$

Share Your Profit/Loss

韭菜变主力

Feb 5 00:54

$Regeneron Pharmaceuticals (REGN.US)$ In traditional technical analysis, you would think this is likely reversed given the engulfing pattern with strong volume at an earnings event. But in this trending market, a higher high has to be established.